Imaging studies on dopamine transporter and depression: A review of literature and suggestions for future research

Journal of Psychiatric Research

Volumn 51, Issue 1, 2014, Pages 7-18

  Camardese, G ^a   Di Giuda, D ^a   Di Nicola, M ^a   Cocciolillo, F ^a   Giordano, A ^a   Janiri, L ^a   Guglielmo, R ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Depression; Dopamine transporter; Mood disorders; Neuroimaging; PET; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IOMETOPANE I 123; METHYL (2 EXO 3 EXO) 8 METHYL 3 (4 METHYLPHENYL) 8 AZABICYCLO[3.2.1]OCTANE 2 CARBOXYLIC ACID C 11; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; NOR 2 BETA CARBOMETHOXY 3 BETA (4 IODOPHENYL) TROPANE I 123; NORADRENALIN TRANSPORTER; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; TRACER; UNCLASSIFIED DRUG; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

ANHEDONIA; DEPRESSION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DSM-IV; DSM-IV-TR; GENETIC POLYMORPHISM; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROFILE OF MOOD STATES; PSYCHOMOTOR RETARDATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW;

DEPRESSION; DOPAMINE TRANSPORTER; MOOD DISORDERS; NEUROIMAGING; PET; SPECT;

BRAIN; DEPRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; NEUROIMAGING; RADIOPHARMACEUTICALS;

EID: 84893947647     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.12.006     Document Type: Review

References (77)

1. aan het Rot M., Mathew S.J., Charney D.S. Neurobiological mechanisms in major depressive disorder. CMAJ 2009, 180:305-313.
2. Amsterdam J.D., Newberg A.B., Soeller I., Shults J. Greater striatal dopamine transporter density may be associated with major depressive episode. JAffect Disord 2012, 141:425-431.
3. Argyelan M., Szabo Z., Kanyo B., Tanacs A., Kovacs Z., Janka Z., et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. JAffect Disord 2005, 89:115-123.
4. Badiavas K., Molyvda E., Iakovou I., Tsolaki M., Psarrakos K., Karatzas N. SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging 2011, 38:764-773.
5. Bajaj N., Hauser R.A., Grachev I.D. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. JNeurol Neurosurg Psychiatry 2013, 84:1288-1295.
6. Bergstrom K.A., Halldin C., Hall H., Lundkvist C., Ginovart N., Swahn C.G., et al. Invitro and invivo characterisation of nor-beta-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med 1997, 24:596-601.
7. Bowden C., Theodorou A.E., Cheetham S.C., Lowther S., Katona C.L., Crompton M.R., et al. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res 1997, 752:227-233.
8. Bowers M.B., Heninger G.R., Gerbode F. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients. Int J Neuropharmacol 1969, 8:255-262.
9. Brunswick D.J., Amsterdam J.D., Mozley P.D., Newberg A. Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry 2003, 160:1836-1841.
10. Carroll F.I., Scheffel U., Dannals R.F., Boja J.W., Kuhar M.J. Development of imaging agents for the dopamine transporter. Med Res Rev 1995, 15:419-444.
11. Cosgrove K.P., Krantzler E., Frohlich E.B., Stiklus S., Pittman B., Tamagnan G.D., et al. Dopamine and serotonin transporter availability during acute alcohol withdrawal: effects of comorbid tobacco smoking. Neuropsychopharmacology 2009, 34:2218-2226.
12. Cosgrove K.P., Tellez-Jacques K., Pittman B., Petrakis I., Baldwin R.M., Tamagnan G., et al. Dopamine and serotonin transporter availability in chronic heroin users: a [(1)(2)(3)I]beta-CIT SPECT imaging study. Psychiatry Res 2010, 184:192-195.
13. Crits-Christoph P., Newberg A., Wintering N., Ploessl K., Gibbons M.B., Ring-Kurtz S., et al. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend 2008, 98:70-76.
14. D'Aquila P.S., Collu M., Gessa G.L., Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000, 405:365-373.
15. Di Giuda D., Camardese G., Bentivoglio A.R., Cocciolillo F., Guidubaldi A., Pucci L., et al. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2012, 39:1937-1948.
16. Djang D.S., Janssen M.J., Bohnen N., Booij J., Henderson T.A., Herholz K., et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. JNucl Med 2012, 53:154-163.
17. Dresel S.H., Kung M.P., Plossl K., Meegalla S.K., Kung H.F. Pharmacological effects of dopaminergic drugs on invivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med 1998, 25:31-39.
18. Drevets W.C. Neuroimaging studies of mood disorders. Biol Psychiatry 2000, 48:813-829.
19. Elovainio M., Jokela M., Kivimaki M., Pulkki-Raback L., Lehtimaki T., Airla N., et al. Genetic variants in the DRD2 gene moderate the relationship between stressful life events and depressive symptoms in adults: cardiovascular risk in young Finns study. Psychosom Med 2007, 69:391-395.
20. Farde L., Halldin C., Muller L., Suhara T., Karlsson P., Hall H. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse 1994, 16:93-103.
21. Gordon I., Weizman R., Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996, 298:27-30.
22. Gottesman, Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003, 160:636-645.
23. Guttman M., Burkholder J., Kish S.J., Hussey D., Wilson A., DaSilva J., et al. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997, 48:1578-1583.
24. Hasler G., Drevets W.C., Manji H.K., Charney D.S. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004, 29:1765-1781.
25. Heinz A., Goldman D., Jones D.W., Palmour R., Hommer D., Gorey J.G., et al. Genotype influences invivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000, 22:133-139.
26. Hiltunen J., Akerman K.K., Kuikka J.T., Bergstrom K.A., Halldin C., Nikula T., et al. Iodine-123 labeled nor-beta-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. Eur J Nucl Med 1998, 25:19-23.
27. Hou H., Yin S., Jia S., Hu S., Sun T., Chen Q., et al. Decreased striatal dopamine transporters in codeine-containing cough syrup abusers. Drug Alcohol Depend 2011, 118:148-151.
28. Hsiao M.C., Lin K.J., Liu C.Y., Beck Schatz D. The interaction between dopamine transporter function, gender differences, and possible laterality in depression. Psychiatry Res 2013, 211:72-77.
29. Hsieh P.C., Lee I.H., Yeh T.L., Chen K.C., Huang H.C., Chen P.S., et al. Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression - a dual-isotope SPECT study. Psychiatry Res 2010, 184:157-161.
30. Ichikawa J., Meltzer H.Y. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol 1995, 281:255-261.
31. Jacobsen L.K., Staley J.K., Malison R.T., Zoghbi S.S., Seibyl J.P., Kosten T.R., et al. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 2000, 157:1134-1140.
32. Jia S.W., Wang W., Liu Y., Wu Z.M. Neuroimaging studies of brain corpus striatum changes among heroin-dependent patients treated with herbal medicine, U'finer capsule. Addict Biol 2005, 10:293-297.
33. Johanson C.E., Frey K.A., Lundahl L.H., Keenan P., Lockhart N., Roll J., et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 2006, 185:327-338.
34. Kilbourne E.J., Nankova B.B., Lewis E.J., McMahon A., Osaka H., Sabban D.B., et al. Regulated expression of the tyrosine hydroxylase gene by membrane depolarization. Identification of the responsive element and possible second messengers. JBiol Chem 1992, 267:7563-7569.
35. Klimek V., Schenck J.E., Han H., Stockmeier C.A., Ordway G.A. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiatry 2002, 52:740-748.
36. Kugaya A., Seneca N.M., Snyder P.J., Williams S.A., Malison R.T., Baldwin R.M., et al. Changes in human invivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003, 28:413-420.
37. Laasonen-Balk T., Kuikka J., Viinamaki H., Husso-Saastamoinen M., Lehtonen J., Tiihonen J. Striatal dopamine transporter density in major depression. Psychopharmacology (Berl) 1999, 144:282-285.
38. Laine T.P., Ahonen A., Torniainen P., Heikkila J., Pyhtinen J., Rasanen P., et al. Dopamine transporters increase in human brain after alcohol withdrawal. Mol Psychiatry 1999, 4:189-191. 104-185.
39. Laruelle M., Baldwin R.M., Malison R.T., Zea-Ponce Y., Zoghbi S.S., al-Tikriti M.S., et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993, 13:295-309.
40. Lattanzi L., Dell'Osso L., Cassano P., Pini S., Rucci P., Houck P.R., et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002, 4:307-314.
41. Lehto S., Tolmunen T., Joensuu M., Saarinen P.I., Vanninen R., Ahola P., et al. Midbrain binding of [123I]nor-beta-CIT in atypical depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1251-1255.
42. Lehto S.M., Tolmunen T., Kuikka J., Valkonen-Korhonen M., Joensuu M., Saarinen P.I., et al. Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study. Neurosci Lett 2008, 441:291-295.
43. Leventhal A.M., Pettit J.W., Lewinsohn P.M. Characterizing major depression phenotypes by presence and type of psychomotor disturbance in adolescents and young adults. Depress Anxiety 2008, 25:575-592.
44. Lykouras L., Markianos M., Hatzimanolis J., Malliaras D., Stefanis C. Biogenic amine metabolites in delusional (psychotic) depression and melancholia subtypes of major depression. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:1261-1271.
45. Malison R.T., Best S.E., van Dyck C.H., McCance E.F., Wallace E.A., Laruelle M., et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry 1998, 155:832-834.
46. Malison R.T., Price L.H., Berman R., van Dyck C.H., Pelton G.H., Carpenter L., et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998, 44:1090-1098.
47. Martinez D., Gelernter J., Abi-Dargham A., van Dyck C.H., Kegeles L., Innis R.B., et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001, 24:553-560.
48. Martinot M., Bragulat V., Artiges E., Dolle F., Hinnen F., Jouvent R., et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 2001, 158:314-316.
49. Mayberg H.S., Liotti M., Brannan S.K., McGinnis S., Mahurin R.K., Jerabek P.A., et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999, 156:675-682.
50. McCann U.D., Szabo Z., Vranesic M., Palermo M., Mathews W.B., Ravert H.T., et al. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 2008, 200:439-450.
51. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. JNeurosci 1998, 18:8417-8422.
52. Meyer J.H., Kruger S., Wilson A.A., Christensen B.K., Goulding V.S., Schaffer A., et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport 2001, 12:4121-4125.
53. Neumeister A., Willeit M., Praschak-Rieder N., Asenbaum S., Stastny J., Hilger E., et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med 2001, 31:1467-1473.
54. Newberg A., Amsterdam J., Shults J. Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nucl Med Commun 2007, 28:3-6.
55. Newberg A., Lerman C., Wintering N., Ploessl K., Mozley P.D. Dopamine transporter binding in smokers and nonsmokers. Clin Nucl Med 2007, 32:452-455.
56. Nobin A., Bjorklund A. Topography of the monoamine neuron systems in the human brain as revealed in fetuses. Acta Physiol Scand Suppl 1973, 388:1-40.
57. Piccini P.P. Dopamine transporter: basic aspects and neuroimaging. Mov Disord 2003, 18(Suppl.7):S3-S8.
58. Pirker W., Asenbaum S., Kasper S., Walter H., Angelberger P., Koch G., et al. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain invivo. JNeural Transm Gen Sect 1995, 100:247-256.
59. Pizzagalli D.A., Jahn A.L., O'Shea J.P. Toward an objective characterization of an anhedonic phenotype: a signal-detection approach. Biol Psychiatry 2005, 57:319-327.
60. Roy A., Karoum F., Pollack S. Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry 1992, 49:447-450.
61. Rush A.J., Thase M.E., Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003, 53:743-753.
62. Sarchiapone M., Carli V., Camardese G., Cuomo C., Di Giuda D., Calcagni M.L., et al. Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 2006, 147:243-248.
63. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122:509-522.
64. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 2001, 158:1206-1214.
65. Sekine Y., Minabe Y., Ouchi Y., Takei N., Iyo M., Nakamura K., et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003, 160:1699-1701.
66. Shang Y., Gibbs M.A., Marek G.J., Stiger T., Burstein A.H., Marek K., et al. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. JClin Psychopharmacol 2007, 27:71-75.
67. Shi J., Zhao L.Y., Copersino M.L., Fang Y.X., Chen Y., Tian J., et al. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol 2008, 579:160-166.
68. Tatsch K., Poepperl G. Quantitative approaches to dopaminergic brain imaging. QJ Nucl Med Mol Imaging 2012, 56:27-38.
69. Tiihonen J., Kuikka J., Bergstrom K., Hakola P., Karhu J., Ryynanen O.P., et al. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat Med 1995, 1:654-657.
70. Tremblay L.K., Naranjo C.A., Graham S.J., Herrmann N., Mayberg H.S., Hevenor S., et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005, 62:1228-1236.
71. van de Giessen E., de Win M.M., Tanck M.W., van den Brink W., Baas F., Booij J. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. JNucl Med 2009, 50:45-52.
72. van Dyck C.H., Malison R.T., Jacobsen L.K., Seibyl J.P., Staley J.K., Laruelle M., et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. JNucl Med 2005, 46:745-751.
73. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001, 158:377-382.
74. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Hitzemann R., Ding Y.S., et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 1996, 20:1594-1598.
75. Wu H., Lou C., Huang Z., Shi G. SPECT imaging of dopamine transporters with (99m)Tc-TRODAT-1 in major depression and Parkinson's disease. JNeuropsychiatry Clin Neurosci 2011, 23:63-67.
76. Yang Y.K., Yao W.J., Yeh T.L., Lee I.H., Chen P.S., Lu R.B., et al. Decreased dopamine transporter availability in male smokers - a dual isotope SPECT study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:274-279.
77. Yang Y.K., Yeh T.L., Yao W.J., Lee I.H., Chen P.S., Chiu N.T., et al. Greater availability of dopamine transporters in patients with major depression-a dual-isotope SPECT study. Psychiatry Res 2008, 162:230-235.